Facebook
Twitter
LinkedIn
Forward
Focus on Evaporation: Frontline Views on the Future of Dry Eye Disease Treatment (Online CE Monograph)
Activity Description and Purpose
Dry eye disease (DED) is a common disease that can affect visual function, quality of life, and outcomes of ocular surgeries. Most people with DED have the evaporative subtype that is a result of meibomian gland dysfunction (MGD). Effective management for MGD-related DED depends on establishing the correct diagnosis. This educational activity presents overviews of tear film structure and function, MGD pathophysiology, and new and emerging treatments for MGD-related DED. Expert insights for the diagnosis and management of MGD-related DED are provided through a series of case-based discussions. The desired results of this activity are to cement optometrists’ knowledge of the role of evaporation in the pathogenesis of MGD and help them obtain practical strategies for screening, diagnosis, and effective treatment that can improve patient outcomes.
Target Audience
This educational activity is intended for optometrists.
Learning Objectives
After completing this activity, participants will be better able to:
- Review the function of the tear film in maintaining a healthy ocular surface
- Use diagnostic strategies that examine meibomian gland function in routine practice
- Discuss limitations of currently available treatment options for meibomian gland dysfunction–associated dry eye disease
- Evaluate clinical trial data for agents under development for the treatment of meibomian gland dysfunction–associated dry eye disease
Faculty
 | Walter O. Whitley, OD, MBA, FAAO (Chair) |
 | Melissa Barnett, OD, FAAO, FSLS, FBCLA |
 | Marc Bloomenstein, OD, FAAO |
 | Selina McGee, OD, FAAO |
Disclosure Policy
MedEdicus requires that anyone who is in a position to control the content of this educational activity disclose all relevant financial relationships with any commercial interest. Financial relationship information is collected and resolved prior to the educational activity. All relevant relationships have been mitigated.
Faculty
Melissa Barnett, OD, is a consultant for CooperVision and Visus Therapeutics; is an advisory board member of ABB, AccuLens, Allergan, Azura Ophthalmics Ltd, Bausch & Lomb Incorporated, Bruder Healthcare, Dompé US, Inc, EveryDay Contacts*, Johnson & Johnson Vision Care, Inc, Lentechs, Mojo Vision Inc*, Novartis Pharmaceuticals Corporation, OCuSOFT Inc, Orasis Pharmaceuticals, Oyster Point Pharma, Inc, Percept Technologies Inc, RVL Pharmaceuticals, Inc, ScienceBased Health, Sight Sciences, Sun Pharmaceutical Industries, Inc, SynergEyes, Tarsus Pharmaceuticals, Inc, Visus Therapeutics, and Vyluma; and is on the speakers bureau for Gas Permeable Lens Institute, Oyster Point Pharma, Inc, RVL Pharmaceuticals, ScienceBased Health, Synergeyes, Tarsus Pharmaceuticals, Inc, Visus Therapeutics, and Vyluma.
Marc Bloomenstein, OD, is a consultant for Alcon, Allergan, Bausch & Lomb Incorporated, Johnson & Johnson Vision Care, Inc, Novartis Pharmaceuticals Corporation, OCuSOFT Inc, Oyster Point Pharma, Inc, Sight Sciences, Sun Pharmaceutical Industries, Inc, and Thea Pharmaceuticals Limited; and is on the speakers bureau for Allergan, Bausch & Lomb Incorporated, Oyster Point Pharma, Inc, Sight Sciences, and Sun Pharmaceutical Industries, Inc.
Selina McGee, OD, is a consultant for Aldeyra Therapeutics, Allergan, Avellino, Bruder Healthcare, Cynosure, Dompé US, Inc, Eyevance, Horizon Therapeutics plc, Kala Pharmaceuticals, Lumenis, Novartis Pharmaceuticals Corporation, Ocuphire Pharma, Optovue, Incorporated, Oyster Point Pharma, Inc, RVL Pharmaceuticals, Inc, ScienceBased Health, Sun Pharmaceutical Industries, Inc, Tarsus Pharmaceuticals, Inc, Thea Pharmaceuticals Limited, and Versant Health Holdco, Inc; and is on the speakers bureau for Allergan, Bausch & Lomb Incorporated, Cynosure, Dompé US, Inc, Lumenis, Optovue, Incorporated, and Oyster Point Pharma, Inc.
Walter O. Whitley, OD, MBA, is a consultant for Allergan, Bausch & Lomb Incorporated, Bruder Healthcare, Dompé US, Inc, Kala Pharmaceuticals, Novartis Pharmaceuticals Corporation, Oyster Point Pharma, Inc, Santen Inc, ScienceBased Health, and Sun Pharmaceutical Industries, Inc; and is on the speakers bureau for Allergan, Bausch & Lomb Incorporated, Kala Pharmaceuticals, Oyster Point Pharma, Inc, Santen Inc, and Sun Pharmaceutical Industries, Inc.
* The financial relationship existed during the past 24 months but has now ended.
Planners, Managers, and Writers
MedEdicus planners and managers have no relevant commercial relationships to disclose.
Medical Writer: Cheryl Guttman Krader has individual stocks in Johnson & Johnson Vision Care, Inc.
Accreditation Statement
COPE approved for 2.0 CE credits for optometrists.
COPE Course ID: 85297-TD (Asynchronous)
COPE Course Category: Treatment/Management of Ocular Disease
Administrator: 
Disclosure of Commercial Support
MedEdicus has received commercial support from Bausch & Lomb Incorporated for this activity in the form of an unrestricted educational grant.
The content of this COPE-accredited CE activity was planned and prepared independently by MedEdicus without input from members of an ineligible company.
Off-Label Discussion
This educational activity may include discussion of unlabeled and/or investigational uses of drugs or devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Sponsored by 
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the State University of New York College of Optometry, MedEdicus LLC, or Bausch & Lomb Incorporated.
This CE activity is copyrighted to MedEdicus LLC ©2023. All rights reserved. 289
Available Credit
- 2.00 COPE